Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alopecia | 8 | 2022 | 45 | 3.310 |
Why?
|
| Skin Neoplasms | 14 | 2022 | 375 | 2.770 |
Why?
|
| Melanoma | 6 | 2022 | 335 | 1.890 |
Why?
|
| Hair Follicle | 6 | 2022 | 37 | 1.510 |
Why?
|
| Facial Dermatoses | 2 | 2017 | 14 | 1.190 |
Why?
|
| Scalp | 4 | 2020 | 47 | 1.140 |
Why?
|
| Nevus, Pigmented | 4 | 2022 | 30 | 1.060 |
Why?
|
| Inflammation | 4 | 2021 | 1030 | 1.040 |
Why?
|
| Cytokines | 2 | 2020 | 866 | 1.010 |
Why?
|
| Eosinophils | 2 | 2022 | 60 | 0.960 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 3 | 2022 | 11 | 0.940 |
Why?
|
| Epidermis | 2 | 2020 | 42 | 0.860 |
Why?
|
| Hemangioma | 2 | 2020 | 51 | 0.850 |
Why?
|
| Traction | 1 | 2022 | 10 | 0.830 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2020 | 7 | 0.730 |
Why?
|
| Dermoscopy | 2 | 2018 | 14 | 0.730 |
Why?
|
| Chemokine CCL26 | 1 | 2019 | 1 | 0.690 |
Why?
|
| Chemokine CCL24 | 1 | 2019 | 1 | 0.690 |
Why?
|
| Chemokine CCL11 | 1 | 2019 | 9 | 0.690 |
Why?
|
| Cytoplasm | 2 | 2017 | 155 | 0.680 |
Why?
|
| Eosinophilia | 1 | 2019 | 47 | 0.660 |
Why?
|
| Dermatitis | 1 | 2019 | 28 | 0.660 |
Why?
|
| Cell Nucleus | 2 | 2017 | 305 | 0.640 |
Why?
|
| Nevus | 1 | 2017 | 17 | 0.610 |
Why?
|
| Insurance Carriers | 1 | 2017 | 9 | 0.600 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2017 | 14 | 0.600 |
Why?
|
| Laser Therapy | 1 | 2017 | 54 | 0.600 |
Why?
|
| Vascular Malformations | 1 | 2017 | 19 | 0.590 |
Why?
|
| Aminoquinolines | 1 | 2017 | 14 | 0.590 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 52 | 0.590 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 689 | 0.570 |
Why?
|
| Hand Dermatoses | 1 | 2016 | 10 | 0.570 |
Why?
|
| Keratosis | 1 | 2016 | 17 | 0.570 |
Why?
|
| Foot Dermatoses | 1 | 2016 | 12 | 0.570 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 186 | 0.540 |
Why?
|
| Humans | 41 | 2022 | 68618 | 0.530 |
Why?
|
| Fibrosis | 4 | 2020 | 371 | 0.490 |
Why?
|
| Carcinoma in Situ | 3 | 2017 | 47 | 0.420 |
Why?
|
| Diagnosis, Differential | 7 | 2022 | 1140 | 0.390 |
Why?
|
| Skin | 4 | 2018 | 451 | 0.380 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1070 | 0.360 |
Why?
|
| Cicatrix | 2 | 2022 | 60 | 0.350 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2020 | 629 | 0.320 |
Why?
|
| Keratinocytes | 2 | 2019 | 68 | 0.320 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 1174 | 0.310 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 508 | 0.310 |
Why?
|
| Sweat Glands | 2 | 2016 | 10 | 0.280 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2017 | 46 | 0.280 |
Why?
|
| Skin Diseases | 2 | 2019 | 122 | 0.270 |
Why?
|
| Retrospective Studies | 8 | 2020 | 7277 | 0.270 |
Why?
|
| Melanocytes | 3 | 2020 | 23 | 0.260 |
Why?
|
| Hair | 2 | 2020 | 46 | 0.220 |
Why?
|
| Syndrome | 2 | 2020 | 255 | 0.220 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 2 | 2020 | 27 | 0.220 |
Why?
|
| Female | 14 | 2022 | 38074 | 0.200 |
Why?
|
| Biopsy | 6 | 2020 | 540 | 0.200 |
Why?
|
| Pemphigus | 2 | 2018 | 12 | 0.200 |
Why?
|
| Oncogenes | 1 | 2022 | 71 | 0.190 |
Why?
|
| Platelet-Rich Plasma | 1 | 2020 | 6 | 0.190 |
Why?
|
| Biological Factors | 1 | 2020 | 11 | 0.190 |
Why?
|
| Myosin Type V | 1 | 2020 | 1 | 0.190 |
Why?
|
| Receptor, trkC | 1 | 2020 | 6 | 0.190 |
Why?
|
| Gene Fusion | 1 | 2020 | 4 | 0.190 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 18 | 0.190 |
Why?
|
| Alopecia Areata | 1 | 2020 | 17 | 0.180 |
Why?
|
| Forehead | 2 | 2017 | 13 | 0.180 |
Why?
|
| Phimosis | 1 | 2020 | 2 | 0.180 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 49 | 0.180 |
Why?
|
| Skin Abnormalities | 1 | 2020 | 11 | 0.180 |
Why?
|
| Angiokeratoma | 1 | 2020 | 1 | 0.180 |
Why?
|
| Education, Medical | 1 | 2022 | 147 | 0.180 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2022 | 148 | 0.180 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 88 | 0.180 |
Why?
|
| Immunotherapy | 1 | 2022 | 215 | 0.170 |
Why?
|
| Paraffin Embedding | 1 | 2020 | 47 | 0.170 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 2019 | 1 | 0.170 |
Why?
|
| Joint Instability | 1 | 2020 | 87 | 0.170 |
Why?
|
| Workflow | 1 | 2020 | 100 | 0.170 |
Why?
|
| Autoantibodies | 2 | 2018 | 434 | 0.160 |
Why?
|
| Male | 13 | 2020 | 37321 | 0.160 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2018 | 15 | 0.160 |
Why?
|
| Middle Aged | 8 | 2020 | 21147 | 0.160 |
Why?
|
| Pemphigus, Benign Familial | 1 | 2018 | 4 | 0.160 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 168 | 0.160 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2018 | 5 | 0.160 |
Why?
|
| Leg Dermatoses | 1 | 2018 | 6 | 0.150 |
Why?
|
| Intense Pulsed Light Therapy | 1 | 2017 | 1 | 0.150 |
Why?
|
| Low-Level Light Therapy | 1 | 2017 | 4 | 0.150 |
Why?
|
| Angiofibroma | 1 | 2017 | 4 | 0.150 |
Why?
|
| Lymphatic Abnormalities | 1 | 2017 | 2 | 0.150 |
Why?
|
| Granuloma, Pyogenic | 1 | 2017 | 5 | 0.150 |
Why?
|
| Rosacea | 1 | 2017 | 5 | 0.150 |
Why?
|
| Pemphigoid, Bullous | 1 | 2018 | 13 | 0.150 |
Why?
|
| Port-Wine Stain | 1 | 2017 | 7 | 0.150 |
Why?
|
| Epithelioid Cells | 1 | 2017 | 3 | 0.150 |
Why?
|
| Hemangioma, Capillary | 1 | 2017 | 6 | 0.150 |
Why?
|
| Epitopes | 1 | 2018 | 146 | 0.150 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 337 | 0.150 |
Why?
|
| Neurilemmoma | 1 | 2017 | 26 | 0.150 |
Why?
|
| Paget Disease, Extramammary | 1 | 2017 | 5 | 0.150 |
Why?
|
| Paget's Disease, Mammary | 1 | 2017 | 4 | 0.150 |
Why?
|
| Bowen's Disease | 1 | 2017 | 6 | 0.150 |
Why?
|
| Hypopigmentation | 1 | 2017 | 12 | 0.150 |
Why?
|
| Scalp Dermatoses | 1 | 2017 | 13 | 0.150 |
Why?
|
| Photochemotherapy | 1 | 2017 | 59 | 0.150 |
Why?
|
| Lichen Planus | 1 | 2017 | 17 | 0.150 |
Why?
|
| Hyperplasia | 1 | 2017 | 89 | 0.140 |
Why?
|
| Erythema | 1 | 2017 | 18 | 0.140 |
Why?
|
| Hyperpigmentation | 1 | 2017 | 7 | 0.140 |
Why?
|
| Software | 1 | 2020 | 418 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2017 | 87 | 0.140 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2016 | 2 | 0.140 |
Why?
|
| Nevus, Sebaceous of Jadassohn | 1 | 2016 | 2 | 0.140 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2016 | 4 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 151 | 0.140 |
Why?
|
| Cell Nucleolus | 1 | 2016 | 14 | 0.140 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2016 | 16 | 0.140 |
Why?
|
| Microscopy, Polarization | 1 | 2016 | 7 | 0.140 |
Why?
|
| Tinea | 1 | 2016 | 6 | 0.140 |
Why?
|
| Urogenital Neoplasms | 1 | 2016 | 9 | 0.140 |
Why?
|
| Sebaceous Glands | 1 | 2016 | 8 | 0.140 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2016 | 7 | 0.140 |
Why?
|
| Staining and Labeling | 1 | 2016 | 144 | 0.140 |
Why?
|
| Biomarkers | 1 | 2022 | 1593 | 0.130 |
Why?
|
| Mitosis | 1 | 2016 | 76 | 0.130 |
Why?
|
| Fibrillar Collagens | 1 | 2016 | 49 | 0.130 |
Why?
|
| Chromatin | 1 | 2016 | 76 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 74 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 37 | 0.130 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 172 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1753 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4848 | 0.120 |
Why?
|
| Child | 2 | 2022 | 6405 | 0.120 |
Why?
|
| Infant | 1 | 2020 | 2891 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2016 | 384 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1034 | 0.100 |
Why?
|
| Neoplasms | 2 | 2020 | 1667 | 0.100 |
Why?
|
| Aged | 4 | 2020 | 14862 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 561 | 0.090 |
Why?
|
| Adult | 4 | 2020 | 21403 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1536 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2022 | 1342 | 0.070 |
Why?
|
| United States | 1 | 2017 | 7367 | 0.060 |
Why?
|
| Young Adult | 3 | 2020 | 5717 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1465 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2022 | 157 | 0.050 |
Why?
|
| Cell Shape | 1 | 2020 | 37 | 0.050 |
Why?
|
| Thorax | 1 | 2020 | 49 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 159 | 0.050 |
Why?
|
| Cell Size | 1 | 2020 | 76 | 0.050 |
Why?
|
| Immunity | 1 | 2020 | 67 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 66 | 0.040 |
Why?
|
| Health Education | 1 | 2022 | 279 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 191 | 0.040 |
Why?
|
| Desmoglein 3 | 1 | 2018 | 2 | 0.040 |
Why?
|
| Desmosomes | 1 | 2018 | 14 | 0.040 |
Why?
|
| Clobetasol | 1 | 2018 | 1 | 0.040 |
Why?
|
| Autoantigens | 1 | 2018 | 91 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 575 | 0.040 |
Why?
|
| Physical Examination | 1 | 2018 | 152 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 111 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 43 | 0.040 |
Why?
|
| Prednisone | 1 | 2018 | 104 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 189 | 0.040 |
Why?
|
| Phenotype | 1 | 2020 | 947 | 0.040 |
Why?
|
| Chin | 1 | 2017 | 5 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 274 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2022 | 657 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 786 | 0.040 |
Why?
|
| Cell Count | 1 | 2017 | 248 | 0.040 |
Why?
|
| Face | 1 | 2017 | 46 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.040 |
Why?
|
| Neck | 1 | 2017 | 62 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 306 | 0.040 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2016 | 3 | 0.030 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2016 | 6 | 0.030 |
Why?
|
| Keloid | 1 | 2016 | 10 | 0.030 |
Why?
|
| Dermatofibrosarcoma | 1 | 2016 | 8 | 0.030 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2016 | 10 | 0.030 |
Why?
|
| Scleroderma, Localized | 1 | 2016 | 19 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 1752 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2016 | 21 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 1040 | 0.030 |
Why?
|
| Reference Values | 1 | 2017 | 579 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 649 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2016 | 79 | 0.030 |
Why?
|
| Complement C3 | 1 | 2016 | 101 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 800 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 481 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 3187 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1553 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 1196 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.020 |
Why?
|
| Animals | 2 | 2019 | 20881 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3705 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2007 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2279 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3259 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 8912 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 8474 | 0.020 |
Why?
|